Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China
· Delayed Price · Currency is CNY 23.00
-0.20 (-0.86%)
Apr 29, 2026, 3:00 PM CST
Aurisco Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 9,359 | 10,175 | 8,579 | 10,488 | 10,029 | 8,830 | Upgrade
|
| Market Cap Growth | 4.83% | 18.61% | -18.20% | 4.58% | 13.58% | 38.75% | Upgrade
|
| Enterprise Value | 9,436 | 10,126 | 8,317 | 10,056 | 9,726 | 8,296 | Upgrade
|
| Last Close Price | 23.20 | 25.05 | 20.82 | 25.21 | 23.96 | 21.25 | Upgrade
|
| PE Ratio | 24.09 | 22.65 | 24.18 | 36.24 | 47.54 | 52.34 | Upgrade
|
| Forward PE | 17.06 | 16.73 | 18.69 | 30.47 | 39.82 | - | Upgrade
|
| PS Ratio | 5.56 | 5.99 | 5.81 | 8.31 | 9.95 | 10.99 | Upgrade
|
| PB Ratio | 3.44 | 3.83 | 3.68 | 5.33 | 5.96 | 5.86 | Upgrade
|
| P/TBV Ratio | 3.66 | 4.08 | 3.95 | 5.68 | 6.46 | 6.02 | Upgrade
|
| P/FCF Ratio | 70.75 | 142.46 | - | 130.89 | - | - | Upgrade
|
| P/OCF Ratio | 19.34 | 24.14 | 25.81 | 27.20 | 60.27 | 43.81 | Upgrade
|
| EV/Sales Ratio | 5.60 | 5.97 | 5.64 | 7.97 | 9.65 | 10.33 | Upgrade
|
| EV/EBITDA Ratio | 15.36 | 15.53 | 17.73 | 28.49 | 35.61 | 35.42 | Upgrade
|
| EV/EBIT Ratio | 19.70 | 19.01 | 21.53 | 36.07 | 46.71 | 45.40 | Upgrade
|
| EV/FCF Ratio | 71.33 | 141.77 | - | 125.50 | - | - | Upgrade
|
| Debt / Equity Ratio | 0.37 | 0.36 | 0.41 | 0.06 | 0.03 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 1.62 | 1.46 | 2.00 | 0.33 | 0.19 | 0.08 | Upgrade
|
| Debt / FCF Ratio | 7.51 | 13.43 | - | 1.46 | - | - | Upgrade
|
| Net Debt / Equity Ratio | 0.03 | 0.00 | -0.05 | -0.22 | -0.20 | -0.28 | Upgrade
|
| Net Debt / EBITDA Ratio | 0.13 | 0.01 | -0.26 | -1.22 | -1.24 | -1.82 | Upgrade
|
| Net Debt / FCF Ratio | 0.58 | 0.07 | 0.58 | -5.35 | 6.81 | 8.70 | Upgrade
|
| Asset Turnover | 0.41 | 0.42 | 0.46 | 0.55 | 0.54 | 0.49 | Upgrade
|
| Inventory Turnover | 1.13 | 1.13 | 1.15 | 1.18 | 1.28 | 1.45 | Upgrade
|
| Quick Ratio | 2.80 | 2.67 | 2.68 | 1.69 | 1.92 | 3.06 | Upgrade
|
| Current Ratio | 4.22 | 3.95 | 3.85 | 2.73 | 3.38 | 4.87 | Upgrade
|
| Return on Equity (ROE) | 15.26% | 18.01% | 16.50% | 15.83% | 13.05% | 11.63% | Upgrade
|
| Return on Assets (ROA) | 7.35% | 8.22% | 7.49% | 7.56% | 6.93% | 7.02% | Upgrade
|
| Return on Invested Capital (ROIC) | 15.23% | 18.95% | 17.95% | 16.99% | 14.85% | 16.68% | Upgrade
|
| Return on Capital Employed (ROCE) | 12.70% | 14.40% | 11.60% | 13.40% | 12.20% | 12.00% | Upgrade
|
| Earnings Yield | 4.21% | 4.42% | 4.14% | 2.76% | 2.10% | 1.91% | Upgrade
|
| FCF Yield | 1.41% | 0.70% | -2.42% | 0.76% | -0.50% | -0.56% | Upgrade
|
| Dividend Yield | 1.47% | 1.36% | 1.39% | 0.87% | 0.67% | 0.61% | Upgrade
|
| Payout Ratio | 31.50% | 27.63% | 26.72% | 23.15% | 24.81% | 28.52% | Upgrade
|
| Buyback Yield / Dilution | -3.37% | -2.44% | 2.21% | -0.48% | -1.00% | -7.31% | Upgrade
|
| Total Shareholder Return | -1.93% | -1.08% | 3.60% | 0.40% | -0.33% | -6.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.